Biogen's Alzheimer's drug lowers toxic protein
Digest more
The study provides the clearest evidence yet that medicines like BIIB080 might improve cognition, but leaves unclear why ...
An experimental Alzheimer's drug from Biogen, one with a novel approach, slowed decline at comparable rates as approved drugs ...
New mid-stage data from Biogen’s Ionis-partnered therapy diranersen served to both validate the tau hypothesis in Alzheimer’s ...
Biogen Inc. shares declined after additional data from a mid-stage study of its Alzheimer’s drug diranersen failed to show ...
Biogen (BIIB) stock dips as the company updates Phase 2 trial data for diranersen, an Alzheimer’s drug developed with Ionis ...
Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Michael J. Parini as Chief Legal Officer, effective August 3, 2026. Parini will serve as a member of Biogen's Executive Committee and ...
An Alzheimer’s drug from Biogen slowed cognitive decline in a mid-stage trial at roughly comparable rates as approved ...
Biogen's leading tau-targeting candidate has slowed cognitive decline across a suite of different clinical assessments, ...
Biogen stock was down more than 8% Tuesday—on pace for its largest drop since 2020—after the company's experimental Alzheimer ...
Roche (RHHBY) wins FDA priority review for a label expansion for Biogen (BIIB)-partnered kidney disease drug Gazyva with a ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results